

Substitute for form 1449B/PTO

**FIFTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES
JAN 08 2008
January 3, 2008
U.S. GOVERNMENT PRINTING OFFICE: 2008 O-2008-000000
[This document contains several sheets if necessary.]

ATTORNEY DOCKET NO. 3474.1001-011	APPLICATION NO. 10/791,223	
FIRST NAMED INVENTOR Mel H. Epstein	FILING DATE March 2, 2004	
EXAMINER Brian Yong S. Kwon	CONFIRMATION NO. 3953	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER	/Brian-Yong Kwon/	DATE CONSIDERED	05/22/2008
----------	-------------------	-----------------	------------

Substitute for form 1449B/PTO

**FIFTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES

January 3, 2008

(Use several sheets if necessary)

JAN 08 2008

MAILED

PATENT & TRADEMARK OFFICE

ATTORNEY DOCKET NO.
3474.1001-011APPLICATION NO.
10/791,223FIRST NAMED INVENTOR
Mel H. EpsteinFILING DATE
March 2, 2004EXAMINER
Brian Yong S. KwonCONFIRMATION NO.
3953GROUP
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/B.K.	C24	Birks, J. and Flicker, L., "Selegiline For Alzheimer's Disease," (Cochrane Review). In: <i>The Cochrane Library, Issue 4</i> ; pp. 1-35 (2002). Oxford: Update Software.	
	C26	Bishop, J., <i>et al.</i> , "Toxicology and Carcinogenesis Studies of dL-Amphetamine Sulfate in F344/N Rats and B6C3F ₁ Mice," (Technical Report Series No. 387). Research Triangle Park, NC: National Toxicology Program, U. S. Department of Health and Human Services; pp. 3-185 (1991).	
	C286	Brady, <i>et al.</i> , "Stroke Risk Predicts Verbal Fluency Decline in Healthy Older Men," <i>J Gerontol B Psychol Sci Soc Sci</i> , 56:P340-P346 (2001).	
	C287	Caldaruso-Dalton, "Parkinson's Disease: Current and Future Treatments," http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_519.html ; pp 1-9 (1999).	
	C288	Hill, "What is Neuroprotection?" <i>Medical News Today</i> , www.medicalnewstoday.com (10/09/2006).	
	C289	Iudicello, <i>et al.</i> , "Verbal Fluency in HIV Infection: A Meta-Analytic Review," <i>J Int Neuropsychol Soc</i> , 13: 183-189 (2007).	
	C290	The Kenneth T. and Eileen L. Norris Laboratory for Neuroscience Research, "Alzheimer's Disease," <i>University of Southern California School of Pharmacy</i> , pp 1-3 (2007).	
	C291	Khan, "Can Clinical Outcomes be used to Detect Neuroprotection in Multiple Sclerosis?" <i>Neurology</i> , 68:S64-S71, (2007).	
	C292	Piérard, <i>et al.</i> , "Declarative Memory Impairments following a Military Combat Course: Parallel Neuropsychological and Biochemical Investigations," <i>Neuropsychobiology</i> , 49:210-17 (2004).	
	C293	Rajan, "Senior Moments: The Neurobiology of Memory and Aging," <i>Serendip</i> , pp 1-4 (2002).	
	C294	Goodman, <i>et al.</i> , <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th Ed. pp. 202 and 221 (1996).	
↓	C295	Rohatagi, <i>et al.</i> , "Pharmacokinetic Evaluation of a Selegiline Pulsatile Oral Delivery System," <i>Biopharmaceutics & Drug Disposition</i> , 18(8):665-680 (1997).	

EXAMINER	/Brian-Yong Kwon/	DATE CONSIDERED	05/22/2008
765969_1			